Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis
This process consumes cellular methyl donors and, critically, prevents nicotinamide from being recycled into NAD+
When chased to a source, such figures generally attach to small studies, non-standard endpoints, or combination protocols (for example, a peptide paired with a photosensitizer or a procedure), and they do not represent GHK-Cu monotherapy in a rigorous trial
Indeed, we can argue that the effectiveness, easy applicability, safe clinical profile and mechanism of BPC 157 (i.eBPC 157/dopamine/glutamate/NO system) represent an alternative, likely successful, future therapeutic direction for neurological conditions. Additional studies have shown that BPC 157 can offer tendon, ligament, and skeletal muscle healing (Gwyer, et al, 2019) it is apparent that BPC 157 has huge potential and following further development has promise as a therapy to conservatively treat or aid recovery in hypovascular and hypocellular soft tissues such as tendon and ligaments